|
MERTK expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.980400E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.950600E-04 |
| Normal-vs-Stage2 |
1.209030E-01 |
| Normal-vs-Stage3 |
1.458950E-01 |
| Normal-vs-Stage4 |
2.495600E-01 |
| Stage1-vs-Stage2 |
8.113200E-01 |
| Stage1-vs-Stage3 |
7.459600E-02 |
| Stage1-vs-Stage4 |
2.961400E-01 |
| Stage2-vs-Stage3 |
4.546800E-01 |
| Stage2-vs-Stage4 |
5.515400E-01 |
| Stage3-vs-Stage4 |
9.142000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.594700E-04 |
| Normal-vs-AfricanAmerican |
5.958100E-02 |
| Normal-vs-Asian |
5.429800E-02 |
| Caucasian-vs-AfricanAmerican |
4.814400E-01 |
| Caucasian-vs-Asian |
8.620600E-01 |
| AfricanAmerican-vs-Asian |
4.382600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.352100E-02 |
| Normal-vs-Female |
5.778500E-04 |
| Male-vs-Female |
3.497400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.244300E-04 |
| Normal-vs-Age(41-60Yrs) |
3.258600E-03 |
| Normal-vs-Age(61-80Yrs) |
5.435000E-01 |
| Normal-vs-Age(81-100Yrs) |
2.438400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.138200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.317000E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.252400E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.993700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.723700E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.681600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.752800E-04 |
| Classical-VS-Follicular |
6.919000E-03 |
| Classical-VS-Other |
2.135600E-01 |
| Classical-VS-Normal |
1.62526999999413E-05 |
| Tall-VS-Follicular |
6.205200E-01 |
| Tall-VS-Other |
8.609800E-01 |
| Tall-VS-Normal |
9.559200E-01 |
| Follicular-VS-Other |
6.964000E-01 |
| Follicular-VS-Normal |
5.951600E-01 |
| Other-VS-Normal |
8.457200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.350260E-02 |
| Normal-vs-N1 |
8.667600E-01 |
| N0-vs-N1 |
9.309700E-02 |
|
|
